論文・技術情報追加のお知らせ

①Cardiotoxicity in Biological Agent-Targeted Therapy for Rheumatoid Arthritis: ADR Signal Mining and Analysis of Food and Drug Administration Adverse Event Reporting System Database.

関節リウマチにおける生物学的製剤を用いた治療と心毒性の関連性調査

対象DB：FAERS

②Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.

キメラ抗原受容体T細胞療法に伴う心血管系および肺系の有害事象探索研究

対象DB：FAERS

③Privacy-Preserving Anonymity for Periodical Releases of Spontaneous Adverse Drug Event Reporting Data: Algorithm Development and Validation.

SRSデータにおけるプライバシー情報漏洩を防ぐための匿名化手法提案と実証評価

対象DB：FAERS

④A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.

SARS-CoV-2ワクチン（J&J社）接種後のギラン・バレー症候群発症に関する調査研究

対象DB：VAERS

⑤Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients.

COVID-19ワクチン接種後の心筋炎、心膜炎関連調査研究

対象DB：VAERS

⑥Verification of the "Upward Variation in the Reporting Odds Ratio Scores" to Detect the Signals of Drug-Drug Interactions.

薬物間相互作用シグナル検出にむけたupward variation of ROR scoreの検証研究

対象DB：JADER

⑦Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.

COVID-19ワクチン接種後の心血管、神経系、肺系のヨーロッパにおけるイベントデータ分析

対象DB：EudraVigilance

⑧Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis of WHO international database.

mRNA COVID-19ワクチンのインフルエンザワクチンとの安全性比較

対象DB：VigiBase

⑨Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review.

食欲促進剤としてH1抗ヒスタミン薬：cyproheptadineの安全性プロファイリング

対象DB：FPVD